Table 1.

Baseline characteristics of detectable and undetectable patients

		Detectable		Undetectable		p-value
		n	%	n	%
Age at diagnosis	<55	12	17	101	22	0.38
	55–64	39	57	266	58
	≥65	18	26	89	20
Race	White	59	87	391	91	0.23
	Other	9	13	37	9
Relationship	In relationship	51	75	377	86	0.02
	No relationship	17	25	61	14
PSA (ng/ml) at diagnosis	≤6	27	39	228	50	0.09
	>6	42	61	228	50
cT stage	T1	27	39	158	35	0.47
	≥T2	42	61	298	65
Biopsy Gleason	<7	40	58	265	58	0.98
	≥7	29	42	191	42
Percent biopsy cores positive	<33%	18	35	177	54	0.03
	33–66%	25	48	107	33
	>66%	9	17	45	14
D’Amico et al clinical risk group	Low	27	39	164	36	0.32
	Intermediate	25	36	206	45
	High	17	25	86	19
CAPRA clinical risk group	0–2	24	49	172	52	0.38
	3–5	19	39	136	41
	6–10	6	12	22	7
Gleason at pathology	<7	21	33	158	36	0.60
	≥7	43	67	279	64
Positive margins	No	57	83	377	83	0.99
	Yes	12	17	79	17

PSA = prostate-specific antigen; CAPRA = Cancer of the Prostate Risk Assessment.